{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:42Z","timestamp":1788778842542,"version":"build-2803163510"},"reference-count":58,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Center in Poland","doi-asserted-by":"publisher","award":["2018\/31\/B\/NZ6\/03361"],"award-info":[{"award-number":["2018\/31\/B\/NZ6\/03361"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Center in Poland","doi-asserted-by":"publisher","award":["DS 462"],"award-info":[{"award-number":["DS 462"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical University of Lublin","award":["2018\/31\/B\/NZ6\/03361"],"award-info":[{"award-number":["2018\/31\/B\/NZ6\/03361"]}]},{"name":"Medical University of Lublin","award":["DS 462"],"award-info":[{"award-number":["DS 462"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Treatment-free remission (TFR) is achieved in approximately half of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors. The mechanisms responsible for TFR maintenance remain elusive. This study aimed to identify immune markers responsible for the control of residual CML cells early in the TFR (at 3 months), which may be the key to achieving long-term TFR and relapse-free survival (RFS) after discontinuation of imatinib. Our study included 63 CML patients after imatinib discontinuation, in whom comprehensive analysis of changes in the immune system was performed by flow cytometry, and changes in the BCR::ABL1 transcript levels were assessed by RQ-PCR and ddPCR. We demonstrated a significant increase in the percentage of CD8+PD-1+ cells in patients losing TFR. The level of CD8+PD-1+ cells is inversely related to the duration of treatment and incidence of deep molecular response (DMR) before discontinuation. Analysis of the ROC curve showed that the percentage of CD8+PD-1+ cells may be a significant factor in early molecular recurrence. Interestingly, at 3 months of TFR, patients with the e13a2 transcript had a significantly higher proportion of the PD-1-expressing immune cells compared to patients with the e14a2. Our results suggest the important involvement of CD8+PD-1+ cells in the success of TFR and may help in identifying a group of patients who could successfully discontinue imatinib.<\/jats:p>","DOI":"10.3390\/cells13080723","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T12:38:41Z","timestamp":1713789521000},"page":"723","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-1213","authenticated-orcid":false,"given":"Paulina","family":"Kwa\u015bnik","sequence":"first","affiliation":[{"name":"Department of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4417-7831","authenticated-orcid":false,"given":"Joanna","family":"Zaleska","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Link-Lenczowska","sequence":"additional","affiliation":[{"name":"Department of Hematology Diagnostics, Jagiellonian University Hospital in Krak\u00f3w, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9105-1767","authenticated-orcid":false,"given":"Magdalena","family":"Zawada","sequence":"additional","affiliation":[{"name":"Department of Hematology Diagnostics, Jagiellonian University Hospital in Krak\u00f3w, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Wysogl\u0105d","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jagiellonian University Hospital in Krak\u00f3w, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Ochrem","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jagiellonian University Hospital in Krak\u00f3w, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u017cyna","family":"Bober","sequence":"additional","affiliation":[{"name":"Department of Hematooncology and Bone Marrow Transplantation, School of Medicine in Katowice, Medical University of Silesia, 40-032 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Wasilewska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Bia\u0142ystok, 15-276 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Hus","sequence":"additional","affiliation":[{"name":"Department of Hematology, The National Institute of Medicine of the Ministry of Interior and Administration, 02-507 Warsaw, Poland"},{"name":"Department of Clinical Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Szarejko","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Prejzner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Grzybowska-Izydorczyk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of \u0141\u00f3d\u017a, 93-513 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Klonowska-Szymczyk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of \u0141\u00f3d\u017a, 93-513 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"M\u0119dra\u015b","sequence":"additional","affiliation":[{"name":"Department of Hematology, Neoplastic Blood Disorders and Bone Marrow Transplantation in Wroc\u0142aw, 50-367 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-6217","authenticated-orcid":false,"given":"Micha\u0142","family":"Kie\u0142bus","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Sacha","sequence":"additional","affiliation":[{"name":"Chair of Hematology, Jagiellonian University Medical College in Krak\u00f3w, 31-501 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-4030","authenticated-orcid":false,"given":"Krzysztof","family":"Giannopoulos","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJMsr1905447","article-title":"Epidemiologic Signatures in Cancer","volume":"381","author":"Welch","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2017.02.001","article-title":"The Efficacy of Generic Imatinib as First- and Second-Line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia","volume":"17","author":"Islamagic","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/asheducation-2011.1.128","article-title":"Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease","volume":"2011","author":"Hochhaus","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kwa\u015bnik, P., and Giannopoulos, K. (2021). Treatment-Free Remission-A New Aim in the Treatment of Chronic Myeloid Leukemia. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080697"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving Outcomes in Chronic Myeloid Leukemia through Harnessing the Immunological Landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12185-021-03117-7","article-title":"Treatment-Free Remission and Immunity in Chronic Myeloid Leukemia","volume":"113","author":"Ureshino","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_8","first-page":"454","article-title":"Standaryzacja Ilo\u015bciowej Oceny Ekspresji Genu BCR-ABL Metoda RQ-PCR u Chorych Na Przewlek\u0142a Bia\u0142aczke Szpikowa We Wsp\u00f3\u0142pracy z European Leukemia Net","volume":"67","author":"Sacha","year":"2010","journal-title":"Przegla\u0327d Lek."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ejh.13238","article-title":"Variant-Specific Discrepancy When Quantitating BCR-ABL1 E13a2 and E14a2 Transcripts Using the Europe Against Cancer QPCR Assay","volume":"103","author":"Kjaer","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jmoldx.2019.08.007","article-title":"Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia","volume":"22","author":"Franke","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased Proportion of Mature NK Cells Is Associated with Successful Imatinib Discontinuation in Chronic Myeloid Leukemia","volume":"31","author":"Ilander","year":"2016","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 Ligand CD86 on Plasmacytoid Dendritic Cells (PDC) Predicts Risk of Disease Recurrence after Treatment Discontinuation in CML","volume":"31","author":"Inselmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural Killer-Cell Counts Are Associated with Molecular Relapse-Free Survival after Imatinib Discontinuation in Chronic Myeloid Leukemia: The IMMUNOSTIM Study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/sj.leu.2403474","article-title":"Defective Blood Dendritic Cells in Chronic Myeloid Leukemia Correlate with High Plasmatic VEGF and Are Not Normalized by Imatinib Mesylate","volume":"18","author":"Boissel","year":"2004","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1182\/blood-2003-09-3220","article-title":"Imatinib and Plasmacytoid Dendritic Cell Function in Patients with Chronic Myeloid Leukemia","volume":"103","author":"Mohty","year":"2004","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2141.2002.03831.x","article-title":"Low Blood Dendritic Cells in Chronic Myeloid Leukaemia Patients Correlates with Loss of CD34+\/CD38\u2013 Primitive Haematopoietic Progenitors","volume":"119","author":"Mohty","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune Cell Contexture in the Bone Marrow Tumor Microenvironment Impacts Therapy Response in CML","volume":"32","author":"Blom","year":"2018","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed Death 1 Signaling on Chronic Myeloid Leukemia-Specific T Cells Results in T-Cell Exhaustion and Disease Progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML Patients with Deep Molecular Responses to TKI Have Restored Immune Effectors and Decreased PD-1 and Immune Suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK Cells to Immunotherapy Mediated by PD-1\/PD-L1 Blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coi.2015.11.001","article-title":"Immunosurveillance and Immunotherapy of Tumors by Innate Immune Cells","volume":"38","author":"Iannello","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ajh.24226","article-title":"Hodgkin Lymphoma: MOPP Chemotherapy to PD-1 Blockade and Beyond","volume":"91","author":"Ansell","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of Programmed Death 1 Ligands by Murine T Cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and Its Ligands in Tolerance and Immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1085146","DOI":"10.1080\/2162402X.2015.1085146","article-title":"PD-1 Expression on Dendritic Cells Suppresses CD8+T Cell Function and Antitumor Immunity","volume":"5","author":"Lim","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1189\/jlb.0813443","article-title":"Negative Role of Inducible PD-1 on Survival of Activated Dendritic Cells","volume":"95","author":"Park","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.4049\/jimmunol.1100274","article-title":"Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer","volume":"186","author":"Krempski","year":"2011","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.18632\/oncotarget.23691","article-title":"Prognostic Factors Associated with a Stable MR4.5 Achievement in Chronic Myeloid Leukemia Patients Treated with Imatinib","volume":"9","author":"Breccia","year":"2017","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.V126.23.597.597","article-title":"Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC","volume":"126","author":"Bonifacio","year":"2015","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 Transcript Type Influences Response and Outcome in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase CML Treated with Tyrosine Kinase Inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.18632\/oncotarget.27652","article-title":"Influence of Major BCR-ABL1 Transcript Subtype on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated Frontline with Nilotinib","volume":"11","author":"Genthon","year":"2020","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","article-title":"E14a2 BCR-ABL1 Transcript Is Associated with a Higher Rate of Treatment-Free Remission in Individuals with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitor Therapy","volume":"102","author":"Claudiani","year":"2017","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood-2018-99-111083","article-title":"The E13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort","volume":"132","author":"Shanmuganathan","year":"2018","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/cncr.31977","article-title":"The E13a2 BCR-ABL Transcript Negatively Affects Sustained Deep Molecular Response and the Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Receive Tyrosine Kinase Inhibitors","volume":"125","author":"Farina","year":"2019","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.18026","article-title":"Assessment of Quantitative Polymerase Chain Reaction for BCR-ABL1 Transcripts in Chronic Myeloid Leukaemia: Are Improved Outcomes in Patients with E14a2 Transcripts an Artefact of Technology?","volume":"197","author":"Dominy","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41375-022-01612-2","article-title":"Impact of BCR::ABL1 Transcript Type on RT-QPCR Amplification Performance and Molecular Response to Therapy","volume":"36","author":"Salmon","year":"2022","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00432-016-2321-2","article-title":"No Influence of BCR-ABL1 Transcript Types E13a2 and E14a2 on Long-Term Survival: Results in 1494 Patients with Chronic Myeloid Leukemia Treated with Imatinib","volume":"143","author":"Pfirrmann","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cam4.2087","article-title":"Digital PCR Improves the Quantitation of DMR and the Selection of CML Candidates to TKIs Discontinuation","volume":"8","author":"Bernardi","year":"2019","journal-title":"Cancer Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/bjh.17521","article-title":"Assessment of Droplet Digital Polymerase Chain Reaction for Measuring BCR-ABL1 in Chronic Myeloid Leukaemia in an International Interlaboratory Study","volume":"194","author":"Scott","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","article-title":"Chronic Myeloid Leukemia: The Concepts of Resistance and Persistence and the Relationship with the BCR-ABL1 Transcript Type","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic Myeloid Leukemia Patients with the E13a2 BCR-ABL Fusion Transcript Have Inferior Responses to Imatinib Compared to Patients with the E14a2 Transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct Characteristics of E13a2 versus E14a2 BCR-ABL1 Driven Chronic Myeloid Leukemia under First-Line Therapy with Imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.leukres.2017.03.003","article-title":"Is There Immune Surveillance against Chronic Myeloid Leukaemia? Possibly, but Not Much","volume":"57","author":"Gale","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1182\/blood.V98.10.2887","article-title":"Direct Evidence That Leukemic Cells Present HLA-Associated Immunogenic Peptides Derived from the BCR-ABL B3a2 Fusion Protein","volume":"98","author":"Clark","year":"2001","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.16083","article-title":"Longer Treatment Duration and History of Osteoarticular Symptoms Predispose to Tyrosine Kinase Inhibitor Withdrawal Syndrome","volume":"187","author":"Berger","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.clml.2019.12.019","article-title":"Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI","volume":"20","author":"Petrova","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.3324\/haematol.2021.280377","article-title":"Patient- and Physician-Reported Pain after Tyrosine Kinase Inhibitor Discontinuation among Patients with Chronic Myeloid Leukemia","volume":"107","author":"Flynn","year":"2022","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib Withdrawal Syndrome and Longer Duration of Imatinib Have a Close Association with a Lower Molecular Relapse after Treatment Discontinuation: The KID Study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.pain.2014.03.010","article-title":"Inhibition of C-Kit Signaling Is Associated with Reduced Heat and Cold Pain Sensitivity in Humans","volume":"155","author":"Ceko","year":"2014","journal-title":"Pain"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia (EURO-SKI): A Prespecified Interim Analysis of a Prospective, Multicentre, Non-Randomised, Trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of Imatinib in Patients with Chronic Myeloid Leukaemia Who Have Maintained Complete Molecular Remission for at Least 2 Years: The Prospective, Multicentre Stop Imatinib (STIM) Trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and Efficacy of Imatinib Cessation for CML Patients with Stable Undetectable Minimal Residual Disease: Results from the TWISTER Study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of Major Molecular Response as a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients with Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib after Durable Undetectable Disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am. J. Hematol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/8\/723\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:32:20Z","timestamp":1760106740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/8\/723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cells13080723"],"URL":"https:\/\/doi.org\/10.3390\/cells13080723","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]}}}